Jump to Main Contents

Home > Information

Information

Dec. 14, 2023
National Cancer Center Japan and Japan Investment Corporation (JIC) sign agreement to promote comprehensive collaboration
Dec. 1, 2023
Sharing of clinical trial information improves the quality of treatment recommendations by expert panels
Jul. 21, 2023
International Robotic D2 Gastrectomy Seminar at NCC Hospital East
Apr. 19, 2023
World-first confirmation of standard treatment for RAS wild-type colorectal cancer-Paper published in JAMA-
Apr. 12, 2023
Start of Clinical Research of the First Japanese-Produced Next-Generation Photon Counting Computed Tomography
Jan. 24, 2023
Clinical Utility of Circulating Tumor DNA After Surgery for Colorectal Cancer Demonstrated in a Large-Scale Prospective Study -A Step toward Personalized Postoperative Adjuvant Chemotherapy-
Oct. 21, 2022
Introduction video of National Cancer Center Hospital East has been update
Sep. 27, 2022
Teijin, J-TEC, Mitsui Fudosan and NCC to Establish Regenerative Medicine Platform
Aug. 4, 2022
Approximately 43,000 individual patient data of clinical trials with colorectal cancer in Asia and the West shared
Jun. 8, 2022
Virtual Meeting with Peking University First Hospital, Celebrating the Conclusion of Memorandum of Understanding
May 25, 2022
Cooperation with the U.S. National Cancer Institute welcomed by Japan-US leaders in joint statement- role of National Cancer Center highlighted
Mar. 24, 2022
The research article by Dr. Shitara et al. was published in the journal Nature
Feb. 21, 2022
Memorandum of Understanding signed with Peking University First Hospital
Dec. 24, 2021
We have launched English Website of ARCAD Asia
Dec. 23, 2021
Webinar for “Russo -Japanese Joint Symposium”
Dec. 21, 2021
CLIP1-LTK fusion: A novel druggable gene fusion in NSCLC,
identified using LC-SCRUM-Asia genomic screening platform
Nov. 12, 2021
Study shows efficacy of dual-HER2 targeted therapy for patients with HER2-positive colorectal cancer
Nov. 11, 2021
First in-patient transplantation of iPS cell-derived natural killer cells to treat ovarian cancer
Sep. 13, 2021
Webinar on Clinical Research with Guangxi, China
Aug. 24, 2021
Webinar with Guangxi, China
Aug. 16, 2021
Webinar with Neijiang, China
Jun. 30, 2021
Initiation of the 4th-stage industry-academia collaborative Cancer Genome Screening Project for Individualized Medicine in Japan, SCRUM-Japan
May 17, 2021
"MONSTAR-SCREEN" has joined as an official member program in the International Cancer Genome Consortium Accelerating Research in Genomic Oncology (ICGC-ARGO)
May 14, 2021
NATIONAL CANCER CENTER AND EISAI COMMENCE JOINT RESEARCH AND DEVELOPMENT PROJECT “BASIC RESEARCH ON THE DRUG DISCOVERY AND DEVELOPMENT TO ACCELERATE DEVELOPMENT OF ANTICANCER DRUGS IN TREATMENT OF PATIENTS WITH RARE CANCERS AND REFRACTORY CANCERS”, USING PDX WITH HIGH PREDICTABILITY OF CLINICAL OUTCOMES, AND CANCER GENOME DATA
Feb. 2, 2021
Deep Vision: Near-Infrared Imaging and Machine Learning Can Identify Hidden Tumors
Oct. 22, 2020
Webinar with Guangxi Medical University Affiliated Tumor Hospital & Oncology Medical College
Oct. 6, 2020
Development of Precision Medicine for Gastrointestinal Cancers Utility of Liquid Biopsy in Genomic Analysis
Aug. 20, 2020
NCC joins GSK’s oncology development network
Jun. 22, 2020
National Cancer Center Japan and Mitsui Fudosan Agree on Accommodation Facility at the National Cancer Center Hospital East in Kashiwa-no-ha Smart City
Mar. 7, 2019
Kazakhstan Delegation visit
Nov. 19, 2018
Quickening the pace of new anti-cancer agents Attracting nanoparticles full of cancer drugs to the stroma of a tumour is proving key to new therapeutics.
Nov. 13, 2018
Hospital East honoured at ESMO
Aug. 8, 2018
Dr Masaaki Ito appointed Honorary Professor at China-Japan Friendship Hospital
Apr. 3, 2018
Advanced Medical Care Approval Received for Multiplex Gene Panel Testing
to Advancing Personalized Medicine
Mar. 13, 2018
SCRUM-Japan GI-SCREEN Aims for Realizing of Cancer Precision Medicine Utilizing Liquid Biopsy by Analyzing Comprehensive Cancer Genome Alterations in Blood
Feb. 14, 2018
A secondary RET mutation in the activation loop conferring
resistance to vandetanib through allosteric effects